Find information on thousands of medical conditions and prescription drugs.

Zoledronic acid

Zoledronate (Zometa®, Novartis) is a bisphosphonate, used to prevent osteoporosis and skeletal fractures, particularly in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia, particularly hypercalcemia of malignancy. It can also be helpful for treating pain from bone metastases. more...

 Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Zafirlukast
Zagam
Zalcitabine
Zaleplon
Zanaflex
Zanamivir
Zantac
Zarontin
Zelnorm
Zerit
Zestoretic
Zestril
Zetia
Zevalin
Ziagen
Zidovudine
Zileuton
Ziprasidone
Zithromax
Zocor
Zofran
Zoladex
Zoledronic acid
Zolmitriptan
Zoloft
Zolpidem
Zometa
Zomig
Zonegran
Zonisamide
Zopiclone
Zosyn
Zovia
Zovirax
Zyban
Zymar
Zyprexa
Zyrtec
Zyvox

Administration

Usually 4 mg intravenously once a month when given for oncologic purposes. It is given once a year for treatment of osteoporosis.

Side effects

Side effects can include fatigue, anemia, muscle aches, fevers, and swelling in the feet or legs. Zoledronate can cause deterioration in renal function.

A rare complicaiton of zoledronate is osteonecrosis of the jaw. This has mainly been seen in patients with multiple myeloma treated with zoledronate (Durie et al 2005).

Contraindications

  • Poor renal function (e.g. creatinine>3 mg/dL)
  • Pregnancy

Reference

  • Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102. PMID 16000365.

Read more at Wikipedia.org
• [List your site here Free!]

Multimedia Available/FDA Approves Novartis Drug ZOMETA — Zoledronic Acid for Injection — for the Treatment of Cancer-Related Bone Complications
From Business Wire, 2/22/02

Business Editors & Health/Medical Writers

ADVISORY...for FRIDAY (Feb. 22)

NOTE TO EDITORS: Multimedia Assets Available With This Story

Include Logos, Text News Releases, Video

--(BUSINESS WIRE)

The U.S. Food and Drug Administration (FDA) today approved the Novartis drug ZOMETA(R) (zoledronic acid for injection) for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.

These solid tumors include prostate cancer, lung cancer, breast cancer and other solid tumor types. In prostate cancer, patients should have progressed after treatment with at least one hormonal therapy.

The trials that led to the approval of ZOMETA mark the first time any bisphosphonate has demonstrated efficacy in treating bone complications in patients with prostate cancer, lung cancer and other solid tumors.

Further, ZOMETA offers patients, nurses and clinicians a convenient 4 mg, 15-minute infusion time.

You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?5185

This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics and photos.

If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com.

COPYRIGHT 2002 Business Wire
COPYRIGHT 2002 Gale Group

Return to Zoledronic acid
Home Contact Resources Exchange Links ebay